Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Aggregated proteome of MDK model mice

ABSTRACT: MDK is a heparin-binding growth factor and found to be the Aβ associated protein. Through aggregated proteome, we aim to identify DE proteins more associated with plaques by MDK knockout.

INSTRUMENT(S): Q Exactive HF

ORGANISM(S): Mus Musculus (mouse)

TISSUE(S): Brain

SUBMITTER: Shu Yang

LAB HEAD: Junmin Peng

PROVIDER: PXD045746 | Pride | 2025-07-16

REPOSITORIES: Pride

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	MDK_aggregated_cTMT73_F01.1.pepXML	Pepxml
	MDK_aggregated_cTMT73_F01.raw	Raw
	MDK_aggregated_cTMT73_F02.1.pepXML	Pepxml
	MDK_aggregated_cTMT73_F02.raw	Raw
	MDK_aggregated_cTMT73_F03.1.pepXML	Pepxml

Items per page:

1 - 5 of 161

Publications

Midkine Attenuates Aβ Fibril Assembly and Amyloid Plaque Formation.

Zaman Masihuz M Yang Shu S Huang Ya Y Yarbro Jay M JM Hao Yanhong Y Wang Zhen Z Liu Danting D Harper Kiara E KE Soliman Hadeer H Hemphill Alex A Harvey Sarah S Pruett-Miller Shondra M SM Stewart Valerie V Tanwar Ajay Singh AS Kalathur Ravi R Grace Christy R CR Turk Martin M Chittori Sagar S Jiao Yun Y Wu Zhiping Z High Anthony A AA Wang Xusheng X Serrano Geidy E GE Beach Thomas G TG Yu Gang G Yang Yang Y Chen Ping-Chung PC Peng Junmin J

bioRxiv : the preprint server for biology 20250320

Proteomic profiling of Alzheimer's disease (AD) brains has identified numerous understudied proteins, including midkine (MDK), that are highly upregulated and correlated with Aβ since the early disease stage, but their roles in disease progression are not fully understood. Here we present that MDK attenuates Aβ assembly and influences amyloid formation in the 5xFAD amyloidosis mouse model. MDK protein mitigates fibril formation of both Aβ40 and Aβ42 peptides in Thioflavin T fluorescence assay, c ...[more]

PMID: 40166321

Similar Datasets

Whole proteome of MDK model mice

Project description:MDK is a heparin-binding growth factor and found to be the Aβ associated protein. AD mouse model of MDK knockout was established to provide the animal tool to investigate the effect of MDK on AD. Through proteome, we aim to study the Aβ change and identify the DE proteins by MDK knockout to know how MDK affect AD.

2025-07-16 | PXD046539 | Pride

27-plex Tandem Mass Tag Mass Spectrometry for Profiling Brain Proteome in Alzheimer's Disease

Project description:Systematically optimized the protocol for the newly developed 16-plex TMT Reported a novel 27-plex method to enhance the multiplexity for large-scale proteomic profiling, by combining two sets of distinct isobaric tags (11-plex and 16-plex TMT) based on their disparate mass shifts on modified peptides.

2021-04-09 | PXD025261 | Pride

Global Profiling of Lysine Accessibility to Evaluate Protein Structure Changes in Alzheimer’s Disease

Project description:The linear sequence of amino acids in a protein folds into a 3D structure to execute protein activity and function, but it is still challenging to profile the 3D structure at the proteome scale. Here, we present a method of native protein tandem mass tag (TMT) profiling of Lys accessibility and its application to investigate structural alterations in human brain specimens of Alzheimer’s disease (AD).

2021-03-23 | PXD024914 | Pride

Ultra Deep Mouse cerebrospinal fluid (CSF) profiling in Alzheimer’s disease

Project description:Alzheimer's disease (AD) is a neurodegenerative disease, the most common cause of dementia in elderly persons. Accumulation of amyloid plaques in the brain is a characteristic of AD. The requirements for a biomarker include the ability to measure a pathologic process, predict outcome, distinguish disease or measure a pharmacological response to a drug treatment or therapeutic intervention. However, there are no reliable blood based biomarkers for AD. CSF-based protein measurement can be used as a practice for biomarkers in human disease, but comprehensive profiling of Mouse CSF proteome is often masked by the twenty most abundant proteins and impacted by large dynamic range. The commonly used depletion method can alleviate the challenge but introduce additional experimental variation. Here we present a deep analysis of un-depleted CSF proteome by combining 11-plex TMT labeling, exhaustive 2D liquid chromatography fractionation, and high resolution tandem mass spectrometry. This platform is capable of identifying 1056 protein components, covering 6 orders of dynamic range, representing one of the proteome datasets. Finally, a subset of proteins, show statistically significant difference between AD and control samples, which may serve as biomarker candidates for the AD when further correlation can be drawn from the human proteome.

2021-09-09 | PXD018658 | Pride

Deep undepleted human serum proteome profiling toward biomarker discovery for Alzheimer’s disease

Project description:Alzheimer's disease (AD) is a neurodegenerative disease, the most common cause of dementia in elderly persons. Accumulation of amyloid plaques in the brain is a characteristic of AD. The requirements for a biomarker include the ability to measure a pathologic process, predict outcome, distinguish disease or measure a pharmacological response to a drug treatment or therapeutic intervention. However, there are no reliable blood based biomarkers for AD. Serum-based protein measurement is a routine practice for biomarkers in human disease, but comprehensive profiling of serum proteome is often masked by the twenty most abundant proteins and impacted by large dynamic range. The commonly used depletion method can alleviate the challenge but introduce additional experimental variation. Here we present a deep analysis of un-depleted human serum proteome by combining 11-plex TMT labeling, exhaustive 2D liquid chromatography fractionation, and high resolution tandem mass spectrometry. This platform is capable of identifying 4,500 protein components, covering 6 orders of dynamic range, representing one of the deepest serum proteome datasets. Finally, a subset of proteins, show statistically significant difference between AD and control samples, which may serve as biomarker candidates.

2019-04-23 | PXD011482 | Pride

Deep serum proteomics detects sex-influenced signature in a murine model of Alzheimer's disease

Project description:Alzheimer’s disease (AD) is the most common neurodegenerative disorder and is categorized by the deposition of extracellular amyloid plaques and intracellular neurofibrillary tangles. By using mouse models and performing In-depth analysis of the serum proteome has the potential to identify biomarkers that would allow for both early disease detection and measurement of disease progression. Here, we present an ultra-deep, multiplexed, undepleted mouse serum proteome by combining TMT pro-16-plex tandem-mass-tag (TMT)-based labeling, exhaustive two-dimensional liquid chromatography (LC/LC) fractionation, and sample concatenation based on the peptide concentration intensity (low, medium, and high) coupled with high resolution tandem mass spectrometry (MS/MS). We optimized a platform capable of analyzing 4100 protein components (3788 genes), covering a dynamic range of at least 6 orders of magnitude, representing one of the deepest serum proteome analyses by extensive fractionation and concatenation to date. Differential expression (DE) analysis between WT and 5xFAD mouse models showed essentially no protein changes except Lcn11. Interesting, our method detected 65 sex-dependent DE proteins with statistical significance (FDR < 0.05), including some earlier reported molecules related towards AD disease progression Serpina3h, Serpina3c, A1bg, Ncam2, Fgl1, Hamp, Kif15, Man2b2, Egfr, Prl etc, had adequate sensitivity and reproducibility to detect sex-dependent differentially expressed proteins in disease-related pathways. Hence, our newly developed protocol revealed alterations in key sex-related proteins that can be differentiated in serum analysis, both known and novel, which may be relevant to the development of assays for the monitoring and/or treatment various diseases.

2024-05-21 | PXD044306 | Pride

TMT analysis of MOLM-13 cells treated with series 3 CK1a degraders

Project description:Targeted Protein Degradation (TPD) encompasses two approaches that generate small molecules with similar proteasome-dependent mechanisms of action: Proteolysis-Targeting Chimeras (PROTACs) and Molecular Glues (MGs). Our goal is to develop novel MG approaches that exploit the E3 ubiquitin ligase Cereblon (CRBN) to degrade key oncogenic drivers in the leading causes of childhood cancer death: acute myeloid leukemia (AML). This project will identify new vulnerabilities and compounds that degrade hitherto undruggable transcription factors in high-risk acute leukemia (AL) and medulloblastoma (MB). Based on our preliminary data, we hypothesize that these compounds target AML cells via CK1a degradation. Our aims are to understand the mechanism by which compounds SJ001041330, SJ001043149, and SJ001043301 target AML cells using TMT proteomic approach and confirm CK1a degradation by these compounds leading to AML cell death.

2023-12-01 | PXD045230 | Pride

Proteome profiling of MOLM-13 cells treated with proposed CK1α degraders

Project description:Targeted Protein Degradation (TPD) encompasses two approaches that generate small molecules with similar proteasome-dependent mechanisms of action: Proteolysis-Targeting Chimeras (PROTACs) and Molecular Glues (MGs). Our goal is to develop novel MG approaches that exploit the E3 ubiquitin ligase Cereblon (CRBN) to degrade key oncogenic drivers in the leading causes of childhood cancer death: acute myeloid leukemia (AML). This project will identify new vulnerabilities and compounds that degrade hitherto undruggable transcription factors in high-risk acute leukemia (AL) and medulloblastoma (MB). Based on our preliminary data, we hypothesize that each of these compounds (SJ001010039, SJ001010040, SJ001010041, SJ001010047, SJ001010050) degrades CK1α in this cell line and may degrade other proteins. Our aims are to confirm that CK1α is degraded by treatment with each of these compounds and to identify any additional proteins that are targeted for degradation by these compounds.

2023-12-01 | PXD045228 | Pride

TMT analysis of MOLM-13 cells treated with SJ001007095

Project description:Targeted Protein Degradation (TPD) encompasses two approaches that generate small molecules with similar proteasome-dependent mechanisms of action: Proteolysis-Targeting Chimeras (PROTACs) and Molecular Glues (MGs). Our goal is to develop novel MG approaches that exploit the E3 ubiquitin ligase Cereblon (CRBN) to degrade key oncogenic drivers in the leading causes of childhood cancer death: acute myeloid leukemia (AML). This project will identify new vulnerabilities and compounds that degrade hitherto undruggable transcription factors in high-risk acute leukemia (AL) and medulloblastoma (MB). Based on our preliminary data, we hypothesize that compound SJ001007095 targets AML cells independent of GSPT1 degradation. Our aims are to understand the mechanism by which compound SJ001007095 targets AML cells using TMT proteomic approach and identify proteins targeted by the compound SJ001007095 leading to their degradation and consequently AML cell death.

2023-12-01 | PXD045170 | Pride

Profiling of the cortical brain proteome in WT, KO, FAD and FAD/KO mice by TMT-LC/LC-MS/MS

Project description:Proteomic analysis of 5xFAD/Mdk-KO mouse brain reveals proteome-wide changes. This study investigates the impact of midkine (MDK) knockout in 5xFAD mouse model using comprehensive mass spectrometry-based whole proteome profiling. The data demonstrates significant alterations in amyloid formation and microglial activation, providing insights into MDK's protective role in Alzheimer's disease pathology.

2025-07-16 | PXD061103 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data